Ian Thompson, Vice-President of Account & Business Development at Ypsomed, takes us through the recent history of diabetes and obesity therapeutics, the innovative peptide hormone molecules that have reached the market over the past decades and the equally innovative devices developed to deliver them. He addresses the growing challenge of "diabesity" and shows that diabetes and obesity will continue to influence self-injection device development substantially.
To read the white paper, click this text.
To learn more about Drug Delivery and the PODD Conference, please visit drug-delivery.org.
In this article
Ian Thompson
VP of Account & Business Development
Ypsomed
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.